Tumours that have a more luminal and hormone‐receptor positive phenotype could overcome this vulnerability by expressing genes that provide glutamine as product (Glutamine synthase, GS; GLUL) [16] and therefore balance the metabolic flux between glycolysis and glutaminolysis. The gene discussed is GLUL; the disease is neoplasm.